Minimally Invasive Benign Hysterectomy

Overview

A randomised controlled trial comparing hysterectomy by minimally invasive surgical methods; robotic hysterectomy versus vaginal hysterectomy or traditional laparoscopic hysterectomy; outcome and cost analyses.

Full Title of Study: “Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2013

Detailed Description

Laparoscopic surgery is advantageous compared to open surgery in terms of patient morbidity, shorter hospitalization and a more rapid return to daily activities. Robot-assisted laparoscopic surgery have facilitated a higher proportion of minimally invasive surgery first and foremost within gynecologic oncology.It is not clear whether or not this is true for less advanced surgery where a vaginal approach or a traditional laparoscopic approach is possible. Robot-assisted surgery is associated with additional cost due to investment and more expensive surgical equipment. The study is performed to investigate whether or not performing hysterectomy for benign conditions with robotic surgery will be advantageous in terms of shorter operating time, less complications, less conversions to open surgery, and shorter hospital stay in comparison to other minimally invasive procedures such as vaginal hysterectomy and traditional laparoscopic hysterectomy.

Interventions

  • Device: Robotic hysterectomy
    • Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
  • Procedure: Vaginal or laparoscopic hysterectomy
    • Benign hysterectomy performed by traditional minimal invasive procedures.

Arms, Groups and Cohorts

  • Active Comparator: Robotic hysterectomy
    • Minimally invasive hysterectomy by robotic surgery
  • Active Comparator: Vaginal or laparoscopic hysterectomy
    • Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.

Clinical Trial Outcome Measures

Primary Measures

  • Cost of surgery
    • Time Frame: 4 months
    • The cost of surgery includes the actual surgery (anaesthesia, OR-nurse, circulating nurse, doctors and use of the OR) as well as the length of the inpatient stay. The cost for conversions to open surgery, reoperations, readmissions, and any additional cost associated with additional procedures or medical interventions such as radiological examinations and blood transfusions. Based on the estimated cost of surgical material, use of the operating room and cost of anaesthesia each benign hysterectomy performed with robotic surgery would need to be 50 minutes shorter than other minimal invasive procedures to compensate for the additional cost.

Secondary Measures

  • Patient outcome
    • Time Frame: 4 months
    • The number of patients in whom an intraoperative or postoperative complication occurs as well as the seriousness of the complication which occurs and what this entails for the patient in question. This includes conversions to open surgery as well as the need for reoperation and readmission.

Participating in This Clinical Trial

Inclusion Criteria

  • indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer – size of uterus and vagina allows for retrieval by the vaginal route – maximum uterine size equivalent to 16 weeks of pregnancy – informed consent Exclusion Criteria:

  • malignant disease – known extensive intra-abdominal adhesions – anaesthesiological contraindications to laparoscopic surgery – women with pacemaker or other implants where electrosurgery is to be avoided – immunoincompetent women – simultaneous need for prolapse surgery – women with known defects of the hemostasis – allergies towards metronidazole and doxycycline – inability to understand patient information

Gender Eligibility: Female

Minimum Age: 25 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Region Skane
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jan Persson, MD, PhD, Study Director, Department of Obstetrics and Gynecology, Skane University Hospital, Lund

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.